<i>BRCA1</i> Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.

Stefansson, Olafur A; Hilmarsdottir, Holmfridur; Olafsdottir, Kristrun; Tryggvadottir, Laufey; Sverrisdottir, Asgerdur; Johannsson, Oskar T; Jonasson, Jon G; Eyfjord, Jorunn E; Sigurdsson, Stefan

BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.

Stefansson, Olafur A; Hilmarsdottir, Holmfridur; Olafsdottir, Kristrun; Tryggvadottir, Laufey; Sverrisdottir, Asgerdur; Johannsson, Oskar T; Jonasson, Jon G; Eyfjord, Jorunn E; Sigurdsson, Stefan.

Afiliación

Stefansson OA; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Hilmarsdottir H; Cancer Research Laboratory, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Olafsdottir K; Current affiliation deCODE genetics/Amgen Inc., Sturlugata 8, Reykjavik, Iceland.
Tryggvadottir L; Cancer Research Laboratory, Biomedical Center, University of Iceland, Reykjavik, Iceland.
Sverrisdottir A; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Johannsson OT; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Jonasson JG; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
Eyfjord JE; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland.
Sigurdsson S; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland.

JNCI Cancer Spectr ; 4(2): pkz100, 2020 Apr.

Article en En | MEDLINE | ID: mdl-32175521

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: JNCI Cancer Spectr Año: 2020 Tipo del documento: Article País de afiliación: Islandia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google